Background Traditional Chinese medicine (TCM), especially herbal medicine, has been widely used in China and now is also being increasingly used in other countries for the treatment of cardiovascular diseases. Althoug...Background Traditional Chinese medicine (TCM), especially herbal medicine, has been widely used in China and now is also being increasingly used in other countries for the treatment of cardiovascular diseases. Although many studies have demonstrated that certain Chinese herbal products are effective and safe for the treatment of cardiovascular diseases, most of these lack sufficient quality. Therefore, large randomized clinical trials and further scientific research to determine its safety, effectiveness are necessary.QiShen YiQi Dripping Pills (QSYQDP) is a herbal preparation clinically used in the treatment and prevention of coronary artery disease. Preliminary observations have shown its safety and effectiveness. Methods/Design This randomized, controlled trial will recruit 3600 patients with a history of myocardial infarction. Patients will be randomized into two groups by a Centr-Randomized System. One group receives QSYQDP, the other group receive aspirin. This trial protocol will describe eligibility criteria, detailed information on the treatment definition, blinding, endpoints, statistical methods, sample size determination, data management, legal aspects, and the current status of the trial. Discussion This trial is one of the first randomized, controlled clinical trial to evaluate the efficacy and safety of traditional Chinese herbal medicine in the treatment and secondary prevention of coronary artery disease. The results of this study should help to define the role of TCM in modern medical care, as well as to provide the management strategy for CAD patients in China and other countries.展开更多
A pre-treatment methodology for clenbuterol hydrochloride （CLEN） isolation and enrichment in a complex matrix environment was developed through exploiting molecularly imprinted polymers （MIPs）. CLEN-imprinted pol-...A pre-treatment methodology for clenbuterol hydrochloride （CLEN） isolation and enrichment in a complex matrix environment was developed through exploiting molecularly imprinted polymers （MIPs）. CLEN-imprinted pol- ymers were synthesized by the combined use of ally-β-cyclodextrin （ally-13-CD） and methacrylic acid （MAA）, allyl-β-CD and acrylonitrile （AN）, and allyl-β-CD and methyl methacrylate （MMA） as the binary functional monomers. MAA-linked allyl-β-CD MIPs （M-MAA） were characterized by Fourier transform-infrared （FT-IR） spectroscopy and a scanning electron microscope （SEM）. Based upon the results, M-MAA polymers generally proved to be an excellent selective extraction compared to its references： AN-linked allyl-β-CD MIPs （M-AN） and MMA-linked allyl-β-CD MIPs （M-MMA）. M-MAA polymers were eventually chosen to run through a molecularly imprinted solid-phase extraction （MISPE） micro-column to enrich CLEN residues spiked in pig livers. A high recovery was achieved, ranging from 91.03% to 96.76% with relative standard deviation （RSD） ≤4.45%.展开更多
文摘Background Traditional Chinese medicine (TCM), especially herbal medicine, has been widely used in China and now is also being increasingly used in other countries for the treatment of cardiovascular diseases. Although many studies have demonstrated that certain Chinese herbal products are effective and safe for the treatment of cardiovascular diseases, most of these lack sufficient quality. Therefore, large randomized clinical trials and further scientific research to determine its safety, effectiveness are necessary.QiShen YiQi Dripping Pills (QSYQDP) is a herbal preparation clinically used in the treatment and prevention of coronary artery disease. Preliminary observations have shown its safety and effectiveness. Methods/Design This randomized, controlled trial will recruit 3600 patients with a history of myocardial infarction. Patients will be randomized into two groups by a Centr-Randomized System. One group receives QSYQDP, the other group receive aspirin. This trial protocol will describe eligibility criteria, detailed information on the treatment definition, blinding, endpoints, statistical methods, sample size determination, data management, legal aspects, and the current status of the trial. Discussion This trial is one of the first randomized, controlled clinical trial to evaluate the efficacy and safety of traditional Chinese herbal medicine in the treatment and secondary prevention of coronary artery disease. The results of this study should help to define the role of TCM in modern medical care, as well as to provide the management strategy for CAD patients in China and other countries.
基金Project supported by the Department of Science and Technology of Zhejiang Province(No.2013C02022-2/01),China
文摘A pre-treatment methodology for clenbuterol hydrochloride （CLEN） isolation and enrichment in a complex matrix environment was developed through exploiting molecularly imprinted polymers （MIPs）. CLEN-imprinted pol- ymers were synthesized by the combined use of ally-β-cyclodextrin （ally-13-CD） and methacrylic acid （MAA）, allyl-β-CD and acrylonitrile （AN）, and allyl-β-CD and methyl methacrylate （MMA） as the binary functional monomers. MAA-linked allyl-β-CD MIPs （M-MAA） were characterized by Fourier transform-infrared （FT-IR） spectroscopy and a scanning electron microscope （SEM）. Based upon the results, M-MAA polymers generally proved to be an excellent selective extraction compared to its references： AN-linked allyl-β-CD MIPs （M-AN） and MMA-linked allyl-β-CD MIPs （M-MMA）. M-MAA polymers were eventually chosen to run through a molecularly imprinted solid-phase extraction （MISPE） micro-column to enrich CLEN residues spiked in pig livers. A high recovery was achieved, ranging from 91.03% to 96.76% with relative standard deviation （RSD） ≤4.45%.
